68. Int J Hematol. 2018 Jun 21. doi: 10.1007/s12185-018-2479-2. [Epub ahead of print]A unique clinical presentation of de novo acute promyelocytic leukemia as amyeloid sarcoma of the breast.Oravcova I(1)(2), Mikuskova E(3), Leitnerova M(4), Gyarfas J(5), Mlcakova A(5),Szepe P(6), Plank L(6), Demitrovicova L(3), Mikudova V(3), Cingelova S(3), MegoM(7), Drgona L(8).Author information: (1)Department of Oncohematology II, National Cancer Institute, Klenová 1, 83310, Bratislava, Slovakia. iveta.oravcova@nou.sk.(2)Oncohematology Clinic, Faculty of Medicine, Comenius University and NationalCancer Institute, Bratislava, Slovakia. iveta.oravcova@nou.sk.(3)Department of Oncohematology II, National Cancer Institute, Klenová 1, 83310, Bratislava, Slovakia.(4)Department of Medical Genetics, National Cancer Institute, Bratislava,Slovakia.(5)Department of Laboratory Hematology, National Cancer Institute, Bratislava,Slovakia.(6)Department of Pathology, Jessenius Faculty of Medicine, The ComeniusUniversity, Martin, Slovakia.(7)2nd Department of Oncology, Faculty of Medicine, Comenius University andNational Cancer Institute, Bratislava, Slovakia.(8)Oncohematology Clinic, Faculty of Medicine, Comenius University and NationalCancer Institute, Bratislava, Slovakia.Myeloid sarcoma is a rare presentation of acute leukemia as a solid tumor atvarious extramedullary sites. It may present concurrently, before or after theonset of systemic bone marrow leukemia. Unusual clinical localization may lead tomisdiagnosis, or delayed diagnosis and treatment. We describe the first case, to our knowledge, of de novo myeloid sarcoma of the breast confirmed as acutepromyelocytic leukemia. Immunohistochemical analysis, flow cytometry, fluorescentin situ hybridization analysis and molecular analysis using RQ-PCR of tissuesamples should be routine in determining the correct diagnosis in this setting.DOI: 10.1007/s12185-018-2479-2 PMID: 29931624 